Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Johnson & Johnson
Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
December 27th, 2008
Johnson & Johnson (NYSE:JNJ) announced that the Israeli General Director of the Antitrust Authority has approved Johnson & Johnson's proposed acquisition of Omrix Biopharmaceuticals, Inc. (NASDAQ:OMRI), under the Restrictive Trade Practices Law 5748-1988 of Israel. Johnson & Johnson announced its intention to acquire Omrix on November 24, 2008. It commenced, through a new wholly-owned subsidiary, Binder Merger Sub, Inc., a cash tender offer on November 25, 2008, to purchase all outstanding shares of common stock of Omrix for $25.00 per share, less any required withholding taxes. The approval, which was dated December 10, 2008, satisfies one of the...
Source: Law & Health Weekly (2008-12-27)
|
